One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
European Society of Cardiology guidance for the management of cardiovascular disease during the pandemic and a focus on long COVID
Filippo Crea
doi : 10.1093/eurheartj/ehac087
European Heart Journal, Volume 43, Issue 11, 14 March 2022, Pages 1017–1021
From blue lips to artificial intelligence: the history of a US centre of excellence
Judith Ozkan
doi : 10.1093/eurheartj/ehab909
European Heart Journal, Volume 43, Issue 11, 14 March 2022, Pages 1022–1023
Adult Congenital Heart Disease Academy 2021 live meeting—first international in-person cardiology meeting since COVID-19 outbreak
Margarita Brida, Michael A Gatzoulis, Gerhard P Diller, Jolien Roos-Hesselink
doi : 10.1093/eurheartj/ehab856
European Heart Journal, Volume 43, Issue 11, 14 March 2022, Pages 1024–1026
Let us speak about ethics: call-to-action
Peter Lanzer
doi : 10.1093/eurheartj/ehab813
European Heart Journal, Volume 43, Issue 11, 14 March 2022, Pages 1027–1028
SGLT2 inhibitors: the statins of the 21st century
Eugene Braunwald
doi : 10.1093/eurheartj/ehab765
European Heart Journal, Volume 43, Issue 11, 14 March 2022, Pages 1029–1030
Can targeting factor XIa dissociate thrombosis from haemostasis?
Giovanna Liuzzo, Carlo Patrono
doi : 10.1093/eurheartj/ehab871
European Heart Journal, Volume 43, Issue 11, 14 March 2022, Pages 1031–1032
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis
The Task Force for the management of COVID-19 of the European Society of Cardiology
doi : 10.1093/eurheartj/ehab696
European Heart Journal, Volume 43, Issue 11, 14 March 2022, Pages 1033–1058
Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19.
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up
The Task Force for the management of COVID-19 of the European Society of Cardiology
doi : 10.1093/eurheartj/ehab697
European Heart Journal, Volume 43, Issue 11, 14 March 2022, Pages 1059–1103
Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular (CV) disease in association with COVID-19.
Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries
The CAPACITY-COVID Collaborative Consortium and LEOSS Study Group
doi : 10.1093/eurheartj/ehab656
European Heart Journal, Volume 43, Issue 11, 14 March 2022, Pages 1104–1120
Patients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart disease subtypes and in-hospital mortality.
Sharpening focus through wider collaboration: evolving heterogeneity in the bi-directional relationship between cardiovascular disease and COVID-19
Amit Kaura, Jamil Mayet, Charlotte Manisty
doi : 10.1093/eurheartj/ehab622
European Heart Journal, Volume 43, Issue 11, 14 March 2022, Pages 1121–1123
Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme
Elina Larissa Petersen, Alina Goßling, Gerhard Adam, Martin Aepfelbacher, Christian-Alexander Behrendt, Ersin Cavus, Bastian Cheng, Nicole Fischer, Jürgen Gallinat, Simone Kühn, Christian Gerloff, Uwe Koch-Gromus, Martin Härter, Uta Hanning, Tobias B. Huber, Stefan Kluge, Johannes K. Knobloch, Piotr Kuta, Christian Schmidt-Lauber, Marc Lütgehetmann, Christina Magnussen, Carola Mayer, Kai Muellerleile, Julia Münch, Felix Leonard Nägele, Marvin Petersen, Thomas Renné, Katharina Alina Riedl, David Leander Rimmele, Ines Schäfer, Holger Schulz, Enver Tahir, Benjamin Waschki, Jan-Per Wenzel, Tanja Zeller, Andreas Ziegler, Götz Thomalla, Raphael Twerenbold, Stefan Blankenberg
doi : 10.1093/eurheartj/ehab914
European Heart Journal, Volume 43, Issue 11, 14 March 2022, Pages 1124–1137
Long-term sequelae may occur after SARS-CoV-2 infection. We comprehensively assessed organ-specific functions in individuals after mild to moderate SARS-CoV-2 infection compared with controls from the general population.
Post-COVID-19 illness trajectory in community patients: mostly reassuring results
Colin Berry, Hannah K. Bayes
doi : 10.1093/eurheartj/ehac057
European Heart Journal, Volume 43, Issue 11, 14 March 2022, Pages 1138–1140
Impact of COVID-19 pandemic restrictions on ST-elevation myocardial infarction: a cardiac magnetic resonance imaging study
Ivan Lechner, Martin Reindl, Christina Tiller, Magdalena Holzknecht, Felix Troger, Priscilla Fink, Agnes Mayr, Gert Klug, Axel Bauer, Bernhard Metzler, Sebastian J Reinstadler
doi : 10.1093/eurheartj/ehab621
European Heart Journal, Volume 43, Issue 11, 14 March 2022, Pages 1141–1153
The severity of myocardial tissue damage following ST-elevation myocardial infarction (STEMI) strongly determines short- and long-term prognosis. This study explored the impact of the coronavirus disease 2019 (COVID-19) pandemic and associated public health restrictions on infarct severity.
The direct and indirect effects of the COVID-19 pandemic on cardiovascular disease throughout the world
Timothy D Henry, Dean J Kereiakes
doi : 10.1093/eurheartj/ehab782
European Heart Journal, Volume 43, Issue 11, 14 March 2022, Pages 1154–1156
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus
Betty Raman, David A. Bluemke, Thomas F. Lüscher, Stefan Neubauer
doi : 10.1093/eurheartj/ehac031
European Heart Journal, Volume 43, Issue 11, 14 March 2022, Pages 1157–1172
Emerging as a new epidemic, long COVID or post-acute sequelae of coronavirus disease 2019 (COVID-19), a condition characterized by the persistence of COVID-19 symptoms beyond 3 months, is anticipated to substantially alter the lives of millions of people globally. Cardiopulmonary symptoms including chest pain, shortness of breath, fatigue, and autonomic manifestations such as postural orthostatic tachycardia are common and associated with significant disability, heightened anxiety, and public awareness. A range of cardiovascular (CV) abnormalities has been reported among patients beyond the acute phase and include myocardial inflammation, myocardial infarction, right ventricular dysfunction, and arrhythmias. Pathophysiological mechanisms for delayed complications are still poorly understood, with a dissociation seen between ongoing symptoms and objective measures of cardiopulmonary health. COVID-19 is anticipated to alter the long-term trajectory of many chronic cardiac diseases which are abundant in those at risk of severe disease. In this review, we discuss the definition of long COVID and its epidemiology, with an emphasis on cardiopulmonary symptoms. We further review the pathophysiological mechanisms underlying acute and chronic CV injury, the range of post-acute CV sequelae, and impact of COVID-19 on multiorgan health. We propose a possible model for referral of post-COVID-19 patients to cardiac services and discuss future directions including research priorities and clinical trials that are currently underway to evaluate the efficacy of treatment strategies for long COVID and associated CV sequelae.
An attempt to reconcile the contrasting results of analyses on implantable cardioverter-defibrillator shocks during the pandemic
Selçuk Adabag, Mohammad Madjid, Alan Cheng
doi : 10.1093/eurheartj/ehab378
European Heart Journal, Volume 43, Issue 11, 14 March 2022, Page 1173
Cardiac defibrillator therapies during the COVID-19 pandemic: how you look provides perspective
Catherine J O’Shea, Melissa E Middeldorp, Kevin Campbell, Prashanthan Sanders
doi : 10.1093/eurheartj/ehab385
European Heart Journal, Volume 43, Issue 11, 14 March 2022, Pages 1174–1175
VT storm in long QT resulting from COVID-19 vaccine allergy treated with epinephrine
Nicholas R Slater, Kyle R Murphy, Markus B Sikkel
doi : 10.1093/eurheartj/ehab748
European Heart Journal, Volume 43, Issue 11, 14 March 2022, Page 1176
Erratum to: A comprehensive update on cardiovascular surgery: challenges and opportunities
doi : 10.1093/eurheartj/ehac008
European Heart Journal, Volume 43, Issue 11, 14 March 2022, Page 1175
